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ABSTRACT 24 
myo-Inositol is a building block for all inositol-containing phospholipids in 25 
eukaryotes. It can be synthesized de novo from glucose-6-phosphate in the cytosol 26 
and endoplasmic reticulum. Alternatively, it can be taken up from the environment 27 
via Na+- or H+-linked myo-inositol transporters. While Na+-coupled myo-inositol 28 
transporters are found exclusively in the plasma membrane, H+-linked myo-inositol 29 
transporters are detected in intracellular organelles. In Trypanosoma brucei, the 30 
causative agent of human African sleeping sickness, myo-inositol metabolism is 31 
compartmentalized. De novo synthesized myo-inositol is used for 32 
glycosylphosphatidylinositol production in the endoplasmic reticulum, whereas the 33 
myo-inositol taken up from the environment is used for bulk phosphatidylinositol 34 
synthesis in the Golgi. We now provide evidence that the Golgi localized T. brucei 35 
H+-linked myo-inositol transporter (TbHMIT) is essential in bloodstream forms. 36 
Down-regulation of TbHMIT expression by RNA interference blocked 37 
phosphatidylinositol production and inhibited growth of parasites in culture. 38 
Characterization of the transporter in a heterologous expression system demonstrated 39 
a remarkable selectivity of TbHMIT for myo-inositol. It only tolerates a single 40 
modification on the inositol ring, such as the removal of a hydroxyl group, or the 41 
inversion of stereochemistry at a single hydroxyl group relative to myo-inositol. 42 
43 
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INTRODUCTION 44 
myo-Inositol is the precursor for all inositol-containing phospholipids, including 45 
phosphatidylinositol (PI), phosphatidylinositol (poly)phosphates, inositol 46 
phosphorylceramide (IPC) and glycosylphosphatidylinositol (GPI) in all eukaryotes. 47 
In mammalian cells, it is taken up from the environment via sodium/myo-inositol 48 
cotransporters (SMITs) or proton-linked myo-inositol transport (HMIT). Human 49 
SMIT1 and SMIT2 belong to the sodium/glucose transporter family, SGLT/SLC5, 50 
whose members in general mediate uptake of sugars and osmolytes in the 51 
gastrointestinal tract and the kidney (1). They are localized in the plasma membrane 52 
and, besides myo-inositol, also transport xylose and glucose (2, 3). In contrast, the 53 
human HMIT belongs to the sugar/polyol transport facilitators family, GLUT/SLC2A 54 
(4). While most members of this family are also located in the plasma membrane and 55 
regulate sugar homeostasis within the body, subclass III transporters, to which HMIT 56 
belongs, are typically localized intracellularly (5, 6). Interestingly, 57 
GLUT12/SLC2A12 and HMIT/SLC2A13 have been found to co-localize with Golgi 58 
markers (7, 8). Although the substrate specificities of the subclass III GLUT/SLC2A 59 
transporters have been studied in model systems, their physiological roles have not 60 
been firmly established (5, 6). Notably, HMIT completely lacks sugar transport 61 
activity, but instead transports myo-inositol with a Km of approximately 100 µM in a 62 
Xenopus oocyte expression system (8). 63 
Alternatively to uptake, myo-inositol can be synthesized de novo in a reaction 64 
sequence that is conserved from bacteria to mammals, using glucose-6-phosphate as 65 
an initial substrate (9). Endogenously produced as well as imported myo-inositol can 66 
then be used for inositol phospholipid synthesis in a process that is generally believed 67 
to occur in the endoplasmic reticulum (ER). In yeast, plants, protozoa and mammals, 68 
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PI synthase has been localized to the ER using cell fractionation and 69 
immunolocalization studies (10-13). Reconstitution experiments involving purified PI 70 
synthase from Saccharomyces cerevisiae showed that it incorporates asymmetrically 71 
into model vesicles, suggesting that its active site may face the cytosolic side of the 72 
ER in yeast (10). However, the in vivo topology of the active site of PI synthase has 73 
not been determined experimentally. 74 
Interestingly, recent reports in protozoan parasites indicated that the Golgi 75 
represents an additional site for inositol phospholipid synthesis. Direct evidence for 76 
the presence of PI synthase in the Golgi was obtained from immunolocalization 77 
studies in T. brucei bloodstream forms (13), showing that the enzyme has a dual 78 
localization in the ER and Golgi. In support of the Golgi being the site of bulk PI 79 
synthesis in trypanosomes (13), a subsequent study revealed that T. brucei procyclic 80 
forms express a plasma membrane- and Golgi-localized proton-linked myo-inositol 81 
transporter, TbHMIT (14). Down-regulation of TbHMIT inhibited bulk PI formation, 82 
but had no effect on GPI synthesis, demonstrating that PI synthesis in T. brucei is 83 
compartmentalized, with the Golgi representing the site of synthesis of bulk 84 
membrane PI utilizing exogenous myo-inositol (14), and the ER being the site of PI 85 
synthesis for GPI production utilizing de novo synthesized myo-inositol (15). 86 
Transporter-mediated myo-inositol uptake has also been characterized in other 87 
protozoan parasites, including Leishmania donovani (16-19) and Trypanosoma cruzi 88 
(20, 21). These parasites all cause devastating human diseases, including 89 
Leishmaniasis, Chagas disease and human African sleeping sickness. Membrane 90 
transporters are of particular importance for these pathogens to acquire essential 91 
nutrients from their respective hosts and offer attractive targets for rational drug 92 
design and/or the delivery of cytotoxic substrate analogues. The reported dependence 93 
 5 
of T. brucei procyclic forms in culture on exogenous myo-inositol (13, 14) validates 94 
HMIT as potential drug target. 95 
In this report, we extend our previous analysis of myo-inositol uptake in T. brucei 96 
procyclic forms to the pharmacologically more relevant bloodstream form. We 97 
demonstrate that the expression of TbHMIT is essential for normal growth of T. 98 
brucei bloodstream parasites in culture and that it is involved in myo-inositol transport 99 
and PI formation within the Golgi. In addition, we have tested a series of myo-inositol 100 
stereoisomers and structural analogs and related compounds to characterize the 101 
substrate specificity of TbHMIT. 102 
103 
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MATERIALS AND METHODS 104 
Unless otherwise stated, all reagents were of analytical grade and purchased from 105 
Merck (Darmstadt, Germany), Sigma-Aldrich (Buchs, Switzerland) or ICN 106 
Biomedicals (Tägerig, Switzerland). Antibiotics and fetal bovine serum (FBS) were 107 
obtained from Invitrogen (Basel, Switzerland). Primers and sequencing services were 108 
from Microsynth AG (Balgach, Switzerland). Restriction enzymes were purchased 109 
from Thermo Scientific (Wohlen, Switzerland). myo-[2-3H(N)]inositol (15-20 110 
Ci/mmol) (myo-[3H]inositol) and [3H]ethanolamine (40-60 Ci/mmol) were from 111 
American Radiolabeled Chemicals (St. Louis, USA), and dCTP-[-32P] (3000 112 
Ci/mmol) from PerkinElmer Life Sciences (Schwerzenbach, Switzerland). 113 
Trypanosomes and culture conditions – Bloodstream form T. brucei derived from 114 
MiTat 1.2, co-expressing T7 RNA polymerase and a tetracycline repressor (22), were 115 
cultured at 37 °C with 5% CO2 in HMI-9 (23) containing 10% heat-inactivated FBS 116 
and 1 g/ml G418. T. brucei strain 427 procyclic forms were cultured at 27 °C in 117 
SDM-79 (24) containing 5% heat-inactivated FBS.  118 
RNAi-mediated gene silencing – Expression of TbHMIT (Tb927.11.5350) was 119 
down-regulated in T. brucei bloodstream forms by RNAi-mediated gene silencing 120 
using a stem loop construct containing a phleomycin resistance gene. The stem-loop 121 
was excised from plasmid pAG3020 (14) using BamHI and HindIII and re-ligated 122 
into plasmid pMS1720RNAiBSF (25), resulting in plasmid pAG3020-BSF. Plasmid 123 
extraction was performed using the Qiagen Plasmid Midi Kit (Qiagen, Hilden, 124 
Germany) according to the manufacturer’s instructions. Before transfection of T. 125 
brucei bloodstream forms, plasmid DNA was linearized with NotI and precipitated 126 
with phenol and chloroform.  127 
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Generation of hemagglutinin (HA)-tagged TbHMIT – Over-expression of C-128 
terminally 3xHA-tagged TbHMIT was performed using the inducible vector pALC14 129 
as described previously (14), resulting in plasmid pAG3020-BSF2. Before 130 
transfection of T. brucei bloodstream forms, plasmid DNA was linearized with NotI 131 
and isolated with phenol and chloroform. 132 
Stable transfection of trypanosomes and selection of clones – T. brucei 133 
bloodstream forms (4-5  107 cells) were harvested at mid-log phase (0.8-1.1 x 106 134 
cells/ml) by centrifugation at 1250 x g for 10 min, suspended in 100 l of buffer (26) 135 
(90 mM NaPO4, 5 mM KCl, 0.15 mM CaCl2, 50 mM HEPES pH 7.3) and mixed with 136 
10 g of linearized plasmid pAG3020-BSF or pAG3020-BSF2. Electroporation was 137 
performed in a 0.2 cm pulse cuvette (Bio-Rad Laboratories, Reinach, Switzerland) 138 
with a Lonza Nucleofector System (Ruwag Lifescience, Bettlach, Switzerland) using 139 
program FI-115. Electroporated cells were immediately inoculated in 10 ml of HMI-140 
9, containing 10% heat-inactivated FBS, and, if required for selection, 1 µg/ml 141 
phleomycin (for RNAi) or 0.1 g/ml puromycin (for over-expression). Clones were 142 
obtained by limiting dilutions in 24-well plates in HMI-9, containing 10% heat-143 
inactivated FBS, in the presence of 1 µg/ml phleomycin or 0.1 g/ml puromycin. 144 
Antibiotic-resistant clones were tested for the presence of the introduced gene by 145 
PCR. Expression of HA-tagged TbHMIT or induction of RNAi was started by 146 
addition of 1 g/ml tetracycline to parasite cultures. 147 
RNA isolation and Northern blot analysis – Total RNA for Northern blotting was 148 
isolated using the Total SV RNA Extraction Kit (Promega, Dübendorf, Switzerland), 149 
following the manufacturer’s instructions. RNA (10 g) was separated on 150 
formaldehyde-agarose gels (1% agarose, 2% formaldehyde in 3-N-morpholino 151 
propane sulfonic acid) and transferred to GeneScreen Plus nylon membranes 152 
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(PerkinElmer Life Sciences). 32P-Labeled probes were made by random priming the 153 
same PCR products used as inserts in the stem-loop vector using the Prime-a-Gene 154 
Labeling System (Promega). Hybridization was performed overnight at 60 °C in 155 
hybridization buffer containing 7% (w/v) SDS, 1% (w/v) bovine serum albumin, 0.9 156 
mM EDTA, 0.5 M Na2HPO4, pH 7.2, and the membrane was analyzed by 157 
autoradiography using BioMax MS film and a TransScreen-HE intensifying screen. 158 
Ribosomal RNA was visualized on the same formaldehyde-agarose gel by ethidium 159 
bromide staining to control for equal loading. 160 
myo-Inositol uptake assays – T. brucei bloodstream forms (1 x 108 cells) at mid-161 
log phase were harvested by centrifugation at 1250 x g for 10 min and suspended in 162 
phosphate-buffered saline (PBS; 135 mM NaCl, 1.3 mM KCl, 3.2 mM Na2HPO4, 0.5 163 
mM KH2PO4, pH 7.4) at 27 °C. Uptake of myo-[
3H]inositol was measured by adding 164 
50 nM of myo-[3H]inositol to cells at 37 °C. At various time points, uptake of label 165 
was terminated by pelleting 1.5  107 parasites by centrifugation (1500 x g, 5 min, 4 166 
°C) and washing three times in ice-cold PBS. After resuspension of the pellet in 100 167 
µl PBS, radioactivity was measured by scintillation counting using a Packard Tri-168 
Carb 2100TR liquid scintillation analyzer (PerkinElmer Life Sciences). Aliquots of 169 
the parasite suspensions before centrifugation were used to determine the total amount 170 
of radioactivity in the assay.  171 
Metabolic labeling of trypanosomes, lipid extraction and thin layer 172 
chromatography (TLC) – Metabolic labeling of trypanosomes was performed as 173 
described before (27). Briefly, myo-[3H]inositol was added to bloodstream or 174 
procyclic form trypanosomes at mid-log phase, and incubation was continued for 16 175 
h. Cells were harvested by centrifugation at 1750 x g for 10 min, washed with ice-176 
cold Tris-buffered saline (10 mM Tris, 144 mM NaCl, pH 7.4) to remove 177 
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unincorporated label, and bulk phospholipids were extracted twice with 10 ml 178 
chloroform:methanol (CM; 2:1, by vol.). CM fractions were pooled, dried under 179 
nitrogen and resuspended in a small volume of CM. Aliquots were treated with 6 µl 180 
PI-specific phospholipase C from Bacillus cereus (Thermo Scientific, Wohlen, 181 
Switzerland) for 60 min, as described elsewhere (28). Lipids were analyzed by TLC 182 
on Silica Gel 60 plates (Merck) using solvent system 1 composed of 183 
chloroform:methanol:acetic acid:water (25:15:4:2, by vol.) (29). Appropriate lipid 184 
standards were run alongside the samples to be analyzed. Radioactivity was detected 185 
by scanning the air-dried plate with a radioisotope detector (Berthold Technologies, 186 
Regensdorf, Switzerland) and quantified using the Rita Star software provided by the 187 
manufacturer. For analysis of GPI precursors, bloodstream form trypanosomes were 188 
labeled for 16 h with trace amounts of [3H]ethanolamine (28). After harvesting the 189 
cells and extracting bulk lipids as described above, GPI lipids were extracted from the 190 
pellet using chloroform:methanol:water (10:10:3, by vol.) and partitioned between 191 
water and butan-1-ol. [3H]-labeled GPI lipids in the butan-1-ol rich upper phase were 192 
analyzed by TLC using solvent system 2 composed of chloroform:methanol:water 193 
(10:10:3, by vol.) (28). Radioactivity was detected as above. 194 
Mass spectrometry and inositol analysis - Total lipids for mass spectrometry 195 
analysis were extracted using a modified Bligh and Dyer method (30). Briefly, T. 196 
brucei bloodstream forms were collected at mid-log phase, washed with PBS, 197 
resuspended in 100 µl of fresh PBS and transferred to a glass tube. 375 ml 198 
chloroform:methanol (1:2, v/v) was then added and vortexed vigorously for 10-15 199 
min. The sample was made biphasic by the addition of 125 ml chloroform and 125 ml 200 
water, vortexed again and centrifuged at 1000 x g at RT for 5 min. The lower phase 201 
was dried under nitrogen, and stored at 4 °C. Total lipid extracts were dissolved in 15 202 
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ml of choloroform:methanol (1:2, v/v) and 15 ml of acetonitrile:iso-propanol:water 203 
(6:7:2, by vol.) and analysed with a Absceix 4000 QTrap, a triple quadrupole mass 204 
spectrometer equipped with a nanoelectrospray source. Samples were delivered using 205 
a Nanomate interface in direct infusion mode (~125 nl/min). Lipid extracts were 206 
analyzed in both positive and negative ion modes using a capillary voltage of 1.25 207 
kV. Tandem mass spectrometry (MS/MS) scanning (daughter, precursor and neutral 208 
loss scans) was performed using nitrogen as the collision gas with collision energies 209 
between 35-90 V. Each spectrum encompasses at least 50 repetitive scans. MS/MS 210 
spectra were obtained with collision energies as follows: 35-45V, PC/SM in positive 211 
ion mode, parent-ion scanning of m/z 184; 35-55V, PI in negative ion mode, parent-212 
ion scanning of m/z 241; 35-65V, PE in negative ion mode, parent-ion scanning of 213 
m/z 196; 20-35V, PS in negative ion mode, neutral loss scanning of m/z 87; and 40-214 
90V. MS/MS daughter ion scanning was performed with collision energies between 215 
35-90V. Assignment of phospholipid species is based upon a combination of survey, 216 
daughter, precursor and neutral loss scans, as well previous assignments (31). The 217 
identity of phospholipid peaks was verified using the LIPID MAPS: Nature 218 
Lipidomics Gateway (www.lipidmaps.org). 219 
For the inositol analysis, bloodstream forms were collected and lipids were 220 
extracted as above. An internal standard of D6 myo-inositol was added to samples 221 
prior to hydrolysis by strong acid (6M HCl, 110 °C), derivatisation with TMS and 222 
analysis by gas chromatography-mass spectrometry, as published elsewhere (32). 223 
myo-Inositol was quantified and the mean and standard deviations of three separate 224 
analyses were determined. 225 
Microscopy – For immunolocalization of HA-tagged TbHMIT, trypanosomes 226 
were cultured in the presence of tetracycline for 24 h to induce protein expression and 227 
 11 
processed as described (14). HA-tagged proteins were detected using monoclonal 228 
mouse anti-HA antibody (Covance, Munich, Germany) at a dilution of 1:250 in PBS 229 
for 1 h at room temperature. Golgi was visualized by incubating fixed parasites for 1 230 
h at room temperature with rabbit anti-TbGRASP antibody  (kindly provided by G. 231 
Warren, University of Vienna; used at a dilution of 1:1000). Subsequently, the slides 232 
were washed three times with PBS and incubated with the corresponding secondary 233 
antibodies, Alexa Fluor 594 goat anti-mouse IgG and Alexa Fluor 488 goat anti-rabbit 234 
IgG (Invitrogen) at a dilution of 1:1000 and 1:500, respectively, for 1 h at room 235 
temperature. Slides were washed three times with PBS and mounted using 236 
Vectashield containing 4′,6′-diamidino-2-phenylindol (DAPI; Vector Laboratories, 237 
Burlingame, USA). Fluorescence microscopy was performed on a Leica AF6000 238 
microscope (Leica Microsystems, Heerbrugg, Switzerland), using the software 239 
provided by the manufacturer.  240 
Substrate specificity of TbHMIT – Xenopus laevis oocytes were prepared, 241 
injected with Tb927.11.5350 cRNA and defollicated as described previously (14). 242 
Electrophysiological experiments were performed as described before (14). myo-243 
Inositol, epi-quercitol, vibo-quercitol, proto-quercitol, scyllo-inositol, muco-inositol, 244 
allo-inositol, epi-inositol, 1D-chiro-inositol, 1L-chiro-inositol, 1L-epi-2-inosose, 245 
phytic acid, L-quebrachitol, D-pinitol, N-00601 ((1R,4S)-6-methoxycyclohexane-246 
1,2,3,4,5-pentol), N-50350 ((1R,3S)-6-methoxycyclohexane-1,2,3,4,5-pentol) and D-247 
myo-inositol-3-phosphate at 200 µM were applied for 20 s for each measurement. 248 
Potential inhibition of TbHMIT was tested by applying a combination of 200 µM 249 
myo-inositol and one of the compounds described above at an equal concentration. 250 
The resulting signal was compared with that elicited by 200 µM myo-inositol alone. 251 
252 
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RESULTS AND DISCUSSION 253 
Characterization of T. brucei TbHMIT in bloodstream form parasites – To study 254 
if TbHMIT is essential in T. brucei bloodstream forms in culture, we generated 255 
tetracycline-inducible RNAi cell lines against Tb927.11.5350. Transfection of T. 256 
brucei bloodstream forms with plasmid pAG3020-BSF and selection by resistance to 257 
phleomycin resulted in several clones, one of which (A3) was selected for all 258 
subsequent experiments. After 2 days of induction of RNAi by addition of 259 
tetracycline to the culture, parasite growth decreased compared to uninduced (control) 260 
cells (Fig. 1A). Northern blot analysis showed that after 2 days of RNAi, 261 
Tb927.11.5350 mRNA was undetectable (Fig. 1A, inset). The uptake of myo-inositol 262 
into bloodstream form RNAi parasites was measured by adding trace amounts of 263 
myo-[3H]inositol to trypanosomes cultured for 2 days in the absence or presence of 264 
tetracycline and measuring radioactivity in the cell pellets after centrifugation. The 265 
results show that uptake of myo-[3H]inositol into control trypanosomes increased 266 
linearly over 90 min (Fig. 1B). A similar time-dependent linear increase in cell-267 
associated radioactivity was also observed for RNAi parasites after down-regulation 268 
of TbHMIT, however, uptake of myo-[3H]inositol was reduced to approximately half 269 
of that in control cells. To demonstrate that the myo-[3H]inositol that was taken up 270 
was being metabolized into inositol-containing phospholipids, bloodstream forms 271 
cultured in the absence or presence of tetracycline were incubated for 16 h in the 272 
presence of myo-[3H]inositol followed by analysis of radiolabeled lipids by TLC and 273 
radioactivity scanning. In the absence of tetracycline, a single [3H]-labeled lipid class 274 
was detected (Fig. 1C top panel, and Fig. S1A), which was identified as [3H]PI based 275 
on its co-migration with a commercial PI standard and complete susceptibility to PI-276 
specific phospholipase C (Fig. S1B). In parasites after RNAi-mediated down-277 
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regulation of TbHMIT, formation of [3H]PI was reduced by >85% (Fig. 1C, middle 278 
panel). No formation of [3H]inositol phosphorylceramide ([3H]IPC), which is readily 279 
labeled in procyclic forms (Fig. 1C; bottom panel; see also (14)), was observed in un-280 
induced bloodstream forms. This observation is consistent with previous reports 281 
showing that IPC synthesis in T. brucei bloodstream forms is largely absent (31, 33). 282 
In addition, we analyzed the formation of GPI precursor lipids by labeling 283 
bloodstream form parasites cultured in the absence or presence of tetracycline with 284 
[3H]ethanolamine, which gets incorporated into GPIs (28). As shown in Fig. 1D, 285 
formation of the major 3H-labeled GPI precursors, P2 and P3, was readily observed in 286 
parasites after depletion of TbHMIT. This result demonstrates that, as previously 287 
shown in procyclic forms (14), GPI synthesis is not affected by down-regulation of 288 
TbHMIT. 289 
The effect of TbHMIT RNAi on parasite lipid composition was investigated by 290 
extracting the lipids and analyzing them by ES-MS. In negative ion mode a range of 291 
peaks was observed in the un-induced RNAi cells, corresponding to the phospholipid 292 
profile of wild-type parasites (Fig. 2A; see (31) for comparison). These include the 293 
major plasmalogen (alk-enyl acyl) phosphatidylethanolamine (PE) species at 727 m/z, 294 
and PI molecular species at 865, 887 and 913 m/z, corresponding to 36:0, 38:3, and 295 
40:4 PI. Upon induction of the RNAi cells for 48 hours with tetracycline (Fig. 2B), 296 
the intensity of all PI molecular species clearly diminished compared to un-induced 297 
cells, while the plasmalogen PE is still the dominant species (compare Fig. 2A with 298 
Fig. 2B). To confirm the decrease in the PI molecular species, parent ion scans of 241 299 
m/z (collision-induced inositol-1,2-cyclic phosphate fragment) were recorded (Fig. 300 
S2). In extracts of un-induced cells all major PI species are clearly detected (Fig. 301 
S2A). In contrast, in extracts from parasites after 48 h of tetracycline induction the 302 
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intensities of these fragments are drastically decreased (Fig. S2B). In addition, the 303 
amounts of inositol-containing phospholipIds were quantified by measuring the myo-304 
inositol contents in lipid extracts from control and induced cells and normalizing to 305 
cell numbers. The results show that RNAi cells after down-regulation of TbHMIT 306 
only had 79.5 ± 2.5% of myo-inositol-containing lipids compared to non-induced cells 307 
(100 ± 4%; mean values ± standard deviations from three independent experiments).  308 
In the induced cells, apart from the reduction in PI species, the intensities of two 309 
phospholipid species at 762 and 795 m/z had increased (Fig. 2B). These two species 310 
were subjected to fragmentation (Fig. S3A and Fig. S3B, respectively) and identified 311 
as PS 34:0 and PG 38:5, respectively. The only other obvious change in the 312 
phospholipids was observed in positive ion mode (Fig. S4), which shows the choline-313 
phosphate containing species of phosphatidylcholine (PC) and sphingomyelin (SM). 314 
The species at 794 m/z, representing PC 40:4, is clearly decreased in cells after 315 
TbHMIT RNAi compared to un-induced cells (compare Fig. S4A with Fig. S4B). The 316 
cells are obviously trying to compensate for a lack of PI, but the reasons for these 317 
specific changes are unknown, other than to maintain the correct membrane fluidity 318 
for normal cellular functions. 319 
Localization of TbHMIT in T. brucei bloodstream forms – Immunofluorescence 320 
microscopy revealed that ectopically expressed HA-tagged TbHMIT in T. brucei 321 
bloodstream forms localized to a distinct intracellular structure located between the 322 
nucleus and the kinetoplast (Fig. 3). The signal completely co-localized with 323 
TbGRASP (Fig. 3), a marker for the Golgi in T. brucei (34). These findings are in line 324 
with a previous report showing that TbHMIT localizes to the Golgi in T. brucei 325 
procyclic forms (14). 326 
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The Golgi localization of TbHMIT in T. brucei bloodstream forms is noteworthy. 327 
It is believed that PI synthesis occurs on the cytosolic side of the ER (10, 35). It 328 
should be noted, however, that in several studies in plants (11), yeast (36), protozoa 329 
(13) and mammalian cells (12), PI synthase was found to localize not only in the ER, 330 
but also in close proximity to or in the Golgi. As has been demonstrated in T. brucei 331 
(13, 14), PI synthesis in the ER and Golgi may serve different purposes. PI production 332 
in the ER is required for GPI synthesis, while PI produced in the Golgi provides bulk 333 
PI for membrane formation. Based on the localization of TbHMIT in the Golgi, these 334 
results suggest that the last step in PI synthesis, i.e. the attachment of myo-inositol to 335 
CDP-diacylglycerol (CDP-DAG), may occur in the lumen of the Golgi. Interestingly, 336 
a recent report showed that T. brucei CDP-DAG synthase localizes to the ER/Golgi 337 
(37), which would be consistent with PI synthesis taking place in the lumen of the ER 338 
and Golgi. In addition, membrane topology prediction programs indicate that the 339 
active site of T. brucei PI synthase is on the luminal side of the ER. Based on these 340 
observations we propose the following model for compartmentalization of PI 341 
synthesis in T. brucei (Fig. 4). In procyclic forms, myo-inositol is taken up from the 342 
environment via plasma membrane localized TbHMIT; in bloodstream forms, myo-343 
inositol uptake likely occurs via a different transporter. Cytosolic myo-inositol is then 344 
transported into the Golgi via TbHMIT, where it is used for bulk PI and, 345 
subsequently, IPC synthesis. In contrast, de novo synthesis of myo-inositol starts with 346 
the cytosolic conversion of glucose-6-phosphate to inositol-3-phosphate, which in 347 
turn is transported into the ER via an unknown transporter. After dephosphorylation, 348 
newly synthesized myo-inositol is used for PI formation by PI synthase. Subsequently, 349 
PI is translocated from the luminal to the cytosolic face of the ER, where it is used to 350 
initiate GPI synthesis. Recently, a similar mechanism has also been proposed to occur 351 
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in the intra-erythrocytic stage of the malaria parasite, Plasmodium falciparum (38). In 352 
addition, it is worth mentioning that the two PI synthase isoforms described in 353 
Arabidopsis thaliana show different substrate specificities (11), suggesting that two 354 
pools of PI may exist and that these may enter alternative routes of metabolism. 355 
Furthermore, a Golgi localization of PI synthase (11-12, 36) and HMIT (8) has also 356 
been documented in other cells. Thus, we propose that PI formation and metabolism 357 
may be similarly compartmentalized in other eukaryotes as well. 358 
Our data using exogenously added myo-[3H]inositol showed that after depletion 359 
of TbHMIT by RNAi, uptake of myo-[3H]inositol into bloodstream form parasites still 360 
occurred, albeit at a clearly reduced level (Fig. 1B), yet the formation of [3H]PI was 361 
blocked (Fig. 1C). Together with the observed localization of TbHMIT in the Golgi, 362 
these data suggest that myo-[3H]inositol may be taken up in T. brucei bloodstream 363 
forms via a different transporter, located in the plasma membrane, and subsequently 364 
remains metabolically inactive because of the lack of the Golgi-localized TbHMIT, 365 
preventing entry of (cytosolic) myo-[3H]inositol into the Golgi for [3H]PI production. 366 
These results differ slightly from our previous findings in T. brucei procyclic forms 367 
(14), where RNAi against TbHMIT not only blocked [3H]PI formation but also myo-368 
[3H]inositol uptake into parasites. Interestingly, in procyclic forms TbHMIT is not 369 
only present in the Golgi but can also be detected in the plasma membrane, mediating 370 
myo-[3H]inositol uptake into the cell. We are currently addressing these differences 371 
between bloodstream and procyclic forms with further experiments. 372 
Collectively, these results demonstrate that expression of TbHMIT is essential for 373 
normal growth of T. brucei bloodstream forms in culture and that it is involved in 374 
myo-inositol transport into the Golgi for PI formation within the lumen of the Golgi. 375 
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Substrate Specificity of TbHMIT – Perfusion of TbHMIT-expressing Xenopus 376 
laevis oocytes with 200 µM myo-inositol resulted in inward currents of 20 ± 1 nA 377 
(mean value ± standard deviations using 13 oocytes from two independent batches). 378 
The same concentration of myo-inositol did not elicit any currents in water-injected 379 
control oocytes. These results are consistent with a previous report (14). To identify 380 
other potential substrates, oocytes expressing TbHMIT were exposed to a series of 381 
commercially available compounds that are structurally related to myo-inositol (Fig. 382 
5). The currents elicited by these compounds (each applied at a concentration of 200 383 
µM) were compared to those obtained with myo-inositol (Fig. 6). Interestingly, we 384 
found that two quercitol isomers, epi- and vibo-quercitol, elicited currents comparable 385 
to those induced by myo-inositol (76 ± 9% and 83 ±3%, respectively, of the myo-386 
inositol current). In contrast, <5% of the current obtained with myo-inositol was 387 
elicited by another quercitol isomer, proto-quercitol (Fig. 6). Quercitols comprise a 388 
group of 6-C-containing polyols, which compared to the group of inositol isomers 389 
lack one hydroxyl group (Fig. 5) and in the case of proto-quercitol, contain a C1 390 
epimerisation. In addition, small currents (15-25% of the myo-inositol current) were 391 
also obtained with scyllo-inositol, epi-inositol, 1L-chiro-inositol and phytic acid 392 
(myo-inositol-1,2,3,4,5,6-hexakisphosphate). In contrast, the currents induced by 393 
muco-inositol, allo-inositol, 1D-chiro-inositol, 1L-epi-2-inosose (2L-2,3,4,6/5-394 
pentahydroxycyclohexanone), L-quebrachitol (2-O-methyl-L-chiro-inositol), D-395 
pinitol (3-O-methyl-D-chiro-inositol), N-00601 ((1R,4S)-6-methoxycyclohexane-396 
1,2,3,4,5-pentol), N-50350 ((1R,3S)-6-methoxycyclohexane-1,2,3,4,5-pentol) and D-397 
inositol-3-phosphate were <5% of the control myo-inositol current (Fig. 6). 398 
Together, these results provide an insight into the selectivity of the transporter in 399 
terms of functional groups and stereoselectivity. Among the different analogs tested, 400 
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deleting a single hydroxyl group at the 1 (as in (-)-vibo-quercitol) or 6 position (as in 401 
(+)-epi-quercitol) only induced a small decrease in current activity. Inversion of 402 
stereochemistry at a single hydroxyl group relative to myo-inositol was also partly 403 
tolerated, leaving 10-25% of current activity as in scyllo-inositol, epi-inositol, 1L-404 
chiro-inositol and 1D-chiro-inositol. However a double modification of inositol in 405 
terms of inversion of stereochemistry and substitution (deoxy- or methyl ether) 406 
essentially suppressed all current activity, as in quebrachitol, (+)-proto-quercitol, 407 
muco-inositol, allo-inositol and D-pinitol. Note that 1L-epi-2-inosose, which features 408 
a carbonyl group at position 4 of inositol, showed no transporter activity, and that 409 
simple carbohydrates such as glucose, galactose and mannose, which are also 410 
structurally related to inositol, were not accepted by the transporter (see (14)). In 411 
addition, all compounds were analysed for their potential to inhibit TbHMIT-412 
mediated myo-inositol transport in Xenopus oocytes. Co-application with myo-inositol 413 
showed that none of compounds affected the myo-inositol-elicited currents, 414 
demonstrating that at the concentrations tested they did not act as inhibitors of 415 
TbHMIT. Finally, to establish the apparent affinities of TbHMIT for transport of epi- 416 
and vibo-quercitol, Xenopus oocytes were exposed to increasing concentrations of the 417 
compounds and currents were recorded. The results showed that the EC50 values for 418 
epi- and vibo-quercitol (121 µM and 104 µM, respectively; mean values from 2 419 
independent experiments) were in the same range as that for myo-inositol (61 µM; see 420 
(14)). 421 
Together, these data show that TbHMIT is remarkably selective for myo-inositol. 422 
It tolerates a single modification on the inositol ring only, such as the removal of a 423 
hydroxyl group at the 1- or 6-position or the inversion of stereochemistry at a single 424 
hydroxyl group relative to myo-inositol, but no additional modifications. Interestingly, 425 
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TbHMIT (14) and its orthologs from T. cruzi (20) and Leishmania parasites (18, 39) 426 
show no transport activity for monosaccharides. This is in marked contrast to all other 427 
members of the GLUT/SLC2A family, including the intracellularly located members 428 
of the subclass III, which transport many different monosaccharides (1, 5, 6). In 429 
addition, HMIT’s transport specificity is also different from that of the SMITs, which 430 
transport both myo-inositol and monosaccharides (2, 3). 431 
432 
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ABBREVIATIONS 441 
ER, endoplasmic reticulum; ES-MS, electrospray-mass spectrometry; GPI, 442 
glycosylphosphatidylinositol; HA, hemagglutinin; HMIT, proton-linked myo-inositol 443 
transporter; IPC, inositol phosphorylceramide; MS/MS, tandem mass spectrometry; 444 
PC, phosphatidylcholine; PE, phosphatidylethanolamine; PI, phosphatidylinositol; PS, 445 
phosphatidylserine; SM, sphingomyelin; SMIT, sodium/myo-inositol cotransporters; 446 
TLC, thin layer chromatography 447 
448 
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FIGURE LEGENDS 571 
Figure 1. Essentiality of TbHMIT in T. brucei bloodstream forms. (A) Growth of 572 
T. brucei bloodstream form RNAi parasites. Expression of TbHMIT in T. brucei 573 
bloodstream forms was down-regulated by tetracycline-inducible RNAi, and growth 574 
of trypanosomes was monitored for 5 days. Data points represent cumulative cell 575 
numbers of RNAi cells incubated in the absence (filled symbols) or presence (open 576 
symbols) of tetracycline and correspond to mean values ± standard deviations from 577 
three experiments using clone A3. The inset shows a Northern blot analysis of total 578 
RNA extracted from trypanosomes after 2 days of incubation in the absence (-) or 579 
presence (+) of tetracycline (Tet) and probed with [32P]-labeled oligonucleotides used 580 
as inserts for the respective stem-loop vector (top panel); rRNA was stained with 581 
ethidium bromide and used as loading control (bottom panel). Two other RNAi clones 582 
showed similar growth defects and reductions in TbHMIT mRNA levels upon 583 
treatment with tetracycline. (B) myo-inositol uptake by T. brucei bloodstream forms. 584 
After 2 days of incubation in the absence (filled symbols) or presence (open symbols) 585 
of tetracycline, RNAi parasites (clone A3) were washed and subsequently incubated 586 
with trace amounts of myo-[3H]inositol (50 nM, final concentration). After indicated 587 
times, parasites were washed, and the amount of radioactivity in the cell pellet was 588 
measured. Uptake of myo-[3H]inositol at each time point was calculated and plotted as 589 
a function of incubation time. Data points represent mean values ± standard 590 
deviations of triplicate determinations from three independent experiments. (C) 591 
Analysis of myo-[3H]inositol-labeled lipids. T. brucei bloodstream form TbHMIT 592 
RNAi cells (clone A3) were incubated in the absence or presence of tetracycline for 3 593 
days. During the last 16 h of incubation, parasites (2 x 108 cells) were labeled with 25 594 
µCi of myo-[3H]inositol. [3H]-labeled lipids were extracted from parasites incubated 595 
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in the absence (top panel) or presence (middle panel) of tetracycline to down-regulate 596 
TbHMIT, separated by one-dimensional TLC using solvent system 1, and visualized 597 
by scanning the plate (14). Extracts from equal cell equivalents were applied. The 598 
bottom panel represents extracts from T. brucei procyclic forms run on the same TLC 599 
plate for comparison, indicating the migration of [3H]inositol phosphorylceramide 600 
([3H]IPC) and [3H]phosphatidylinositol ([3H]PI). The vertical lines indicate the site of 601 
sample application (left line) and the migration of the solvent front (right line), 602 
respectively. (D) Analysis of [3H]ethanolamine-labeled GPI lipids. Trypanosomes 603 
were cultured in the absence (top panel) or presence (middle panel) of tetracycline for 604 
2 days to down-regulate TbHMIT, and then labeled during 16 h with 605 
[3H]ethanolamine. [3H]GPI lipids were extracted and analyzed by TLC using solvent 606 
system 2. The major GPI lipids, designated P2 and P3, were identified based on 607 
published Rf values (28) and the migration of [
3H]-labeled PP1, i.e. the major GPI 608 
precursor lipid in T. brucei procyclic forms, run on the same plate (bottom panel). The 609 
migration of residual [3H]PE is also indicated. The vertical lines indicate the site of 610 
sample application (left line) and the migration of the solvent front (right line), 611 
respectively. 612 
Figure 2. Phospholipid analysis of T. brucei bloodstream form TbHMIT RNAi 613 
cells. Lipid extracts from parasites incubated in the absence (A) or presence (B) of 614 
tetracycline for 48 hours were analyzed by negative ion ES-MS survey scans (600-615 
1000 m/z (mass/charge)). The major phospholipid classes are annotated: PI, 616 
phosphatidylinositol; PE, phosphatidylethanolamine; EPC, ethanolamine 617 
phosphorylceramide. The arrows in (B) refer to the phospholipid species that increase 618 
or decrease after RNAi against TbHMIT compared to non-induced cells (A). 619 
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Figure 3. Localization of TbHMIT in T. brucei bloodstream forms. Trypanosomes 620 
cultured in the presence of tetracycline for 24 h to induce expression of HA-tagged 621 
TbHMIT were washed, allowed to settle onto microscope slides, fixed with 622 
paraformaldehyde, and permeabilized with Triton X-100. TbHMIT was detected 623 
using anti-HA antibody (first panel) whereas the Golgi was stained with anti-GRASP 624 
antibody (second panel). The third panel shows an overlay of panels A and B, with 625 
DNA stained with DAPI. The corresponding differential interference contrast (DIC) 626 
micrograph is shown in the fourth panel. 627 
Figure 4. Schematic of compartmentalized myo-inositol metabolism in T. brucei. 628 
For details see main text. Glc-6-P, glucose-6-phosphate; GPI, 629 
glycosylphosphatidylinositol; Ins, inositol; Ins-3-P, inositol-3-phosphate; IPC, 630 
inositolphosphoryl ceramide; PI, phosphatidylinositol; TbHMIT, T. brucei H+-631 
coupled myo-inositol transporter; GlcNAc-PI, N-acetylglucosaminyl 632 
phosphatidylinositol; GlcN-PI, glucosamine phosphatidylinositol; TbPIS, T. brucei PI 633 
synthase; TbSLS1, T. brucei sphingolipid synthase 1; TbINO1, T. brucei 1-D-myo-634 
inositol-3-phosphate synthase; TbIMPase, T. brucei inositol monophosphatase. 635 
Figure 5. Structures of the various inositols and analogs tested in this study. The 636 
numbering refers to the parent myo-inositol numbering; the positions and substitutions 637 
with a change relative to myo-inositol are indicated with the carbon number in blue 638 
and highlighted in red color. 639 
Figure 6. Substrate specificity of TbHMIT. Xenopus oocytes expressing TbHMIT 640 
were exposed to 200 µM myo-inositol and a series of structurally related compounds 641 
(all at 200 µM) and the currents were recorded. The bars indicate currents relative to 642 
the response elicited by myo-inositol (mean values ± standard deviations from at least 643 
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3 determinations). N-00601: (1R,4S)-6-methoxycyclohexane-1,2,3,4,5-pentol; N-644 
50350: (1R,3S)-6-methoxycyclohexane-1,2,3,4,5-pentol. 645 
 646 
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SUPPLEMENTARY FIGURES 655 
 656 
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 657 
 658 
Figure S1. Susceptibility of [3H]-labeled lipids to PI-PLC. [3H]-labeled lipids were 659 
extracted from T. brucei bloodstream forms, incubated in the absence (upper panel) or 660 
presence (lower panel) of PI-PLC, and separated by one-dimensional TLC using 661 
solvent system 1. Radioactivity was detected by scanning the plate. 662 
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 663 
 664 
Figure S2. Lipidomic analysis of inositol containing phospholipids from T. brucei 665 
TbHMIT RNAi knock-down cells by ES-MS-MS. Lipid extracts from bloodstream 666 
form parasites incubated in the absence (A) or presence (B) of tetracycline for 48 667 
hours were analyzed by negative ion ES-MS-MS utilising parent ion scans of 241 668 
(600-1000m/z). 669 
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 670 
 671 
Figure S3. Fragmentation of phospholipid species m/z 763 (A) and m/z 795 (B) 672 
from T. brucei TbHMIT RNAi knock-down cells by ES-MS-MS. Fragmentation 673 
reveals that (A) is mainly phosphatidylserine (34:0) and (B) is mainly 674 
phosphatidylglycerol (38:5). 675 
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 677 
Figure S4. Positive ion ES-MS lipidomic analysis of T. brucei TbHMIT RNAi 678 
knock-down cells. Lipid extracts from bloodstream form parasites incubated in the 679 
absence (A) or presence (B) of tetracycline for 48 hours were analyzed by positive ion 680 
ES-MS survey scans (600-1000m/z). 681 
 682 
